Get the content you want anytime you want.

Recent Insights in Understanding the Clinical Impact and Burden of Carbapenem-Resistant Enterobacteriaceae

1. Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013;80(4):225-233.
2. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenemresistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86(3):250-259.
3. Sievert DM, Ricks P, Edwards JR, et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14.
4. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1): 60-67.
5. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. CDC website. drugresistance/threat-report-2013/. Updated July 17, 2014. Accessed November 1, 2016.
6. McNeill R, Nelson DJ, Abutaleb Y. The deadly epidemic America is ignoring: the uncounted. Part 1: off the radar. Reuters website. sidebar-abrcdc-space. Published September 7, 2016. Accessed November 31, 2016
7. Gupta V, Olesky M, Tabak YP, et al. National prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in the ambulatory and acute care settings in the United States in 2015-2016. Poster presented at: ID Week 2016; October 26-30 2016; New Orleans, LA.
8. Silvaggio JL, Terashita D, Marquez P, et al. Development of a regional antibiogram to monitor burden and distribution of MDRO pathogens across the spectrum of care in Los Angeles county. Poster presented at: ID Week 2016; October 26-30 2016; New Orleans, LA.
9. Bartsch SM, Huang SS, Wong KF, et al. Impact of delays between Clinical and Laboratory Standards Institute and Food and Drug Administration revisions of interpretive criteria for carbapenemresistant Enterobacteriaceae. J Clin Microbiol. 2016;54(11): 2757-2762.
10. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenemresistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA. 2015;314(14):1479-1487.
11. van Duin D, Perez F, Rudin SD, et al. Surveillance of carbapenemresistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014;58(7):4035-4041.
12. Evans HL, Lefrak SN, Lyman J, et al. Cost of gram-negative resistance. Critical Care Med. 2007;35(1):89-95.
13. Maragakis LL. Recognition and prevention of multidrug-resistant gram-negative bacteria in the intensive care unit. Critical Care Med. 2010;38(suppl8):S345-S351.
14. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20:1170-1175.
15. Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al; Investigators from the REIPI/ESGBIS/INCREMENT GROUP. A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae. Mayo Clin Proc. 2016;91(10):1362-1371.
16. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance in Enterobacteriaceae among hospitalized patients with urinary tract infection, pneumonia and sepsis increases the risk of receiving inappropriate empiric treatment. Poster presented at: ID Week 2016; October 26-30 2016; New Orleans, LA.
17. Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2016. pii: S1198-743X(16)30389-5.
18. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill. 2014;19(42):pii:20939.
19. Parisi SG, Bartolini A, Santacatterina E, et al. Prevalence of Klebsiella pneumoniae strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 to December 2014. BMC infect Dis. 2015;15:244.
20. Tumbarello M, Viale P, Bassetti M, De Rosa FG, Spanu T, Viscoli C. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study--authors’ response. J Antimicrob Chemother. 2015;70(10):2922.
21. Meletis G, Oustas E, Botziori C, Kakasi E, Koteli A. Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance. New Microbiol. 2015;38(3):417-421.
22. van Duin D, Cober E, Richter SS, et al. Residence in skilled nursing facilities is associated with tigecycline nonsusceptibility in carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2015;36(8): 942-8.
23. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016. pii:ciw636.
24. CARB-X Xccelerating global antibacterial innovation website. Accessed November 2, 2016.
25. Antibiotics currently in clinical development. The Pew Charitable Trusts website. antibiotics-currently-in-clinical-development.pdf. Updated May 2016. Accessed November 4, 2016.
26. Zavante Therapeutics. Safety and efficacy of ZTI-01 (IV fosfomycin) vs piperacillin/tazobactam for treatment cUTI/AP infections (ZEUS). website. NCT02753946. Verified October 2016. Accessed November 1, 2016.  

Advocacy and Research Foundation Partners
We break down our top HIV news stories of 2017. Did you read them all?